SEARCH:   Advanced

Blood, 15 November 2008, Vol. 112, No. 10, pp. 3974-3981. Prepublished online as a Blood First Edition Paper on September 3, 2008; DOI 10.1182/blood-2008-06-161695. This Article Full Text (PDF) All Versions of this Article: blood-2008-06-161695v1 112/10/3974    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Micklethwaite, K. P Articles by Gottlieb, D. J Search for Related Content PubMed PubMed Citation Articles by Micklethwaite, K. P Articles by Gottlieb, D. J Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 6, 2008 Accepted August 18, 2008 Prophylactic infusion of cytomegalovirus specific cytotoxic T-lymphocytes stimulated with Ad5f35pp65 gene modified dendritic cells following allogeneic haemopoietic stem cell transplantation Kenneth P Micklethwaite, Leighton Clancy, Upinder Sandher, Anna M Hansen, Emily Blyth, Vicki Antonenas, Mary M Sartor, Kenneth F Bradstock, and David J Gottlieb* Westmead Millennium Institute, The University of Sydney, Sydney, NSW, Australia Sydney Cellular Therapies Laboratory, Westmead Hospital, Sydney, NSW, Australia Blood and Marrow Transplant Service, Westmead Hospital, Sydney, NSW, Australia * Corresponding author; email: david_gottlieb{at}wmi.usyd.edu.au. Cytomegalovirus (CMV) and its therapy continue to contribute to morbidity and mortality in haemopoietic stem cell transplantation (HSCT). Many studies have demonstrated the feasibility of in-vitro generation of CMV-specific T-cells for adoptive immunotherapy of CMV. Few clinical trials have been performed showing the safety and efficacy of this approach in-vivo. In this study, donor-derived, CMV-specific T-cells were generated for 12 adult HSCT patients by stimulation with dendritic cells transduced with an adenoviral vector encoding the CMV-pp65 protein. Patients received a prophylactic infusion of T-cells after day 28 post-HSCT. There were no infusion related adverse events. CMV DNAemia was detected in 4 patients post-infusion, but was of low level. No patient required CMV-specific pharmacotherapy. Immune reconstitution to CMV was demonstrated by ELISPOT assay in all recipients with rapid increases in predominantly CMV-pp65 directed immunity in 5. Rates of graft versus host disease, infection and death were not increased compared to expected. These results add to the growing evidence of the safety and efficacy of immunotherapy of CMV in HSCT, supporting its more widespread use. This study was registered at www.anzctr.org.au under ID Number: ACTRN12605000213640 CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. M. Leen, A. Christin, G. D. Myers, H. Liu, C. R. Cruz, P. J. Hanley, A. A. Kennedy-Nasser, K. S. Leung, A. P. Gee, R. A. Krance, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation Blood, November 5, 2009; 114(19): 4283 - 4292. [Abstract] [Full Text] [PDF] A. K. L. Cheung, D. J. Gottlieb, B. Plachter, S. Pepperl-Klindworth, S. Avdic, A. L. Cunningham, A. Abendroth, and B. Slobedman The role of the human cytomegalovirus UL111A gene in down-regulating CD4+ T-cell recognition of latently infected cells: implications for virus elimination during latency Blood, November 5, 2009; 114(19): 4128 - 4137. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020